Advanced Imaging in Chronic Pediatric Pulmonary Disease (CPPD)

Advanced Imaging in Chronic Pediatric Pulmonary Disease (CPPD) - ADVANCER study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57065

Enrollment

Registered

2023-10-05

Start date

2025-02-25

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Interventions

MRI scan will be performed. This study will investigate whether 3D Spiro MRI can be used to assess Chronic Pulmonary Disease in comparison to Photon Counting detecter CT scan. Two questionnaires and s

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all  of the following criteria: CF Cohort • children aged 5 to 18 years • CF patients referred for an annual follow-up BPD Cohort • children aged 5 to 18 years • BPD patients referred for follow-up  Asthma Cohort • children aged 5 to 18 years • Difficult-to-treat asthma children referred for CT examination

Exclusion criteria

Exclusion criteria: A potential CPPD subject who meets any of the following criteria will be excluded from participation in this study: Children diagnosed with CF, difficult to treat asthma or BPD under the age of 5Pulmonary exacerbation (CF and Asthma)ClaustrophobiaInability to perform the breathing manoeuvresAny contraindication(s) to undergo MRI 

Design outcomes

Primary

Measure	Time frame
The primary study endpoint is to investigate whether 3D Spiro MRI can be used to assess CCPD compared to PCD-CT: N=90 Research MRIs - PRIME score N=90 Clinical PCD-CTs - PRAGMA score PRAGMA score quantifies lung abnormalities in a hierarchical order, with results expressed as % of total lung volume. PRIME score is an adapted version of the PRAGMA score, for the MRI scan.	—

Secondary

Measure	Time frame
To address the secondary aims, the following secondary study parameters will be collected: • PFTs outcomes o Spirometry (FEV1, FVC, FEV1/FVC, FEF25-75 and FEF75) o Multiple breath washout (Lung clearance index) o Oscillometry at 5-11-19Hz • Research questionnaires data • N=90 Research MRIs - 3D Spiro MRI biomarkers (17), PREFUL MRI outcomes (21) • N=90 Clinical PCD-CTs - BronchusArtery (BA) ratios, Ventilation estimation from registered analysis (VERA) analysis scores, Pulmonary Artery and Vein analysis outcomes	—

Measure

Time frame

To address the secondary aims, the following secondary study parameters will be collected: • PFTs outcomes o Spirometry (FEV1, FVC, FEV1/FVC, FEF25-75 and FEF75) o Multiple breath washout (Lung clearance index) o Oscillometry at 5-11-19Hz • Research questionnaires data • N=90 Research MRIs - 3D Spiro MRI biomarkers (17), PREFUL MRI outcomes (21) • N=90 Clinical PCD-CTs - BronchusArtery (BA) ratios, Ventilation estimation from registered analysis (VERA) analysis scores, Pulmonary Artery and Vein analysis outcomes

—

Countries

Netherlands

Contacts

Public ContactJL Puttelaar

Erasmus MC, Universitair Medisch Centrum Rotterdam

lunganalysis@erasmusmc.nl0107036661

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 27, 2026